Evidence map›Paper›PMID 33281749›Full record

ArticleFrontiers in endocrinology2020

Impact of the Chemokine Receptors CXCR4 and CXCR7 on Clinical Outcome in Adrenocortical Carcinoma.

Irina Chifu, Britta Heinze, Carmina T Fuss, Katharina Lang, Matthias Kroiss, Stefan Kircher, Cristina L Ronchi, Barbara Altieri, Andreas Schirbel, Martin Fassnacht and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Radiopharmaceuticals for Treatment of Adrenocortical Carcinoma.Pharmaceuticals (Basel, Switzerland) · 2023
    Review
  6. Article
  7. CXCR4-targeted theranostics in oncology.European journal of nuclear medicine and molecular imaging · 2022
    Review
  8. Current Status ofDiagnostics (Basel, Switzerland) · 2022
    Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Management of adrenocortical carcinoma: are we making progress?Therapeutic advances in medical oncology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Irina ChifuDivision of Endocrinology and Diabetes, Department of Medicine I, University Hospital of Wuerzburg, University of Wuerzburg, Wuerzburg, Germany.
Britta HeinzeDivision of Endocrinology and Diabetes, Department of Medicine I, University Hospital of Wuerzburg, University of Wuerzburg, Wuerzburg, Germany.
Carmina T FussDivision of Endocrinology and Diabetes, Department of Medicine I, University Hospital of Wuerzburg, University of Wuerzburg, Wuerzburg, Germany.
Katharina LangInstitute of Metabolism and Systems Research, University of Birmingham, Birmingham, United Kingdom.
Matthias KroissDivision of Endocrinology and Diabetes, Department of Medicine I, University Hospital of Wuerzburg, University of Wuerzburg, Wuerzburg, Germany.
Stefan KircherInstitute of Pathology, Interdisciplinary Bank of Biomaterials and Data (ibdw), University of Wuerzburg, Wuerzburg, Germany.
Cristina L RonchiDivision of Endocrinology and Diabetes, Department of Medicine I, University Hospital of Wuerzburg, University of Wuerzburg, Wuerzburg, Germany.
Barbara AltieriDivision of Endocrinology and Diabetes, Department of Medicine I, University Hospital of Wuerzburg, University of Wuerzburg, Wuerzburg, Germany.
Andreas SchirbelComprehensive Cancer Center Mainfranken, University of Wuerzburg, Wuerzburg, Germany.
Martin FassnachtDivision of Endocrinology and Diabetes, Department of Medicine I, University Hospital of Wuerzburg, University of Wuerzburg, Wuerzburg, Germany.
Stefanie HahnerDivision of Endocrinology and Diabetes, Department of Medicine I, University Hospital of Wuerzburg, University of Wuerzburg, Wuerzburg, Germany.
Comprehensive Cancer Center Mainfranken · DEUniversity of Birmingham · GBUniversity of Würzburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemokine receptors have a negative impact on tumor progression in several human cancers and have therefore been of interest for molecular imaging and targeted therapy. However, their clinical and prognostic significance in adrenocortical carcinoma (ACC) is unknown. The aim of this study was to evaluate the chemokine receptor profile in ACC and to analyse its association with clinicopathological characteristics and clinical outcome. A chemokine receptor profile was initially evaluated by quantitative PCR in 4 normal adrenals, 18 ACC samples and human ACC cell line NCI-H295. High expression of CXCR4 and CXCR7 in both healthy and malignant adrenal tissue and ACC cells was confirmed. In the next step, we analyzed the expression and cellular localization of CXCR4 and CXCR7 in ACC by immunohistochemistry in 187 and 84 samples, respectively. These results were correlated with clinicopathological parameters and survival outcome. We detected strong membrane expression of CXCR4 and CXCR7 in 50% of ACC samples. Strong cytoplasmic CXCR4 staining was more frequent among samples derived from metastases compared to primaries (

Indexed as

Gene Expression Regulation, NeoplasticAdrenal Cortex NeoplasmsAdrenocortical CarcinomaBiomarkers, TumorCombined Modality TherapyFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisReceptors, CXCRReceptors, CXCR4Survival RateTumor Cells, CulturedACKR3 protein, humanBiomarkers, TumorCXCR4 protein, humanReceptors, CXCRReceptors, CXCR4adrenocortical carcinomachemokine receptorCXCR4CXCR7prognosis

Identifiers

PMID33281749
PMCPMC7691376
OpenAlexW3098978059

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.